Trading Statement

RNS Number:3951D
Celsis International PLC
28 September 2004


                            CELSIS INTERNATIONAL PLC

               Celsis reports strong trading in pre-close update

   Appointment of Robert W Baird Limited as financial adviser and stockbroker


28 September 2004: Celsis International plc, the microbial detection and
analytical services company, today provides a trading update prior to the
commencement of its close period.

The Group has made excellent progress across both divisions in the first half of
the year and as a result is on track to perform in line with the Board's
expectations for the six months to 30 September 2004.  The Laboratory Group has
benefited from the continuing recovery in the analytical services market which
became evident in the second half of last year as pharmaceutical companies began
to increase expenditure in outsourcing.  In the Product Group, our targeted
marketing initiatives are also yielding excellent results and we expect to
achieve strong revenue growth in this division at the half year.

Celsis is also pleased to announce the appointment of Robert W. Baird Limited as
the Company's financial adviser and stockbroker with immediate effect.

Jay LeCoque, Chief Executive Officer, Celsis International plc commented:

"Celsis has been experiencing strong global growth and is set for an encouraging
first half year.  The Product Group continues to perform well across all of its
market segments.  As we anticipated, the Laboratory Group has strongly rebounded
during this first half and we are confident this will continue into the second
half.

"I am also pleased to announce the appointment of Robert W. Baird as Celsis'
stockbroker.  Baird, who have strong expertise in the life science sector, will
play a key role in supporting Celsis in its ambitious future development.  We
look forward to working with them."

Celsis will announce its interim results for the six months to 30 September
2004, on Wednesday 27 October 2004.  There will be a presentation to analysts on
the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton
Buildings, London, WC2A 1PB.


Enquiries:

Celsis International plc                                     Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Robert W. Baird                                              Tel: [phone]
Shaun Dobson
Xavier de Mol

Financial Dynamics                                           Tel: [phone]
David Yates
Lucy Briggs


Notes to editors

Celsis International plc

Based in Newmarket, UK, Celsis International plc is a microbial detection and
analytical services company operating through two divisions, the Product Group
and the Laboratory Group.

Using its proprietary enzyme technology, the Product Group is the world leader
in the provision of diagnostic systems for the rapid detection of microbial
contamination.  It works in close collaboration with many of the world's leading
pharmaceutical, personal care, food and beverage companies, ensuring the safety
and quality of products bound for consumers.  The Laboratory Group provides
outsourced analytical testing services to pharmaceutical companies to ensure the
stability and chemical composition of their products.

In addition to ensuring product quality and safety for consumers, both divisions
have the capacity to deliver substantial cost savings to Celsis' customers.  By
reducing the time it takes to test and release raw materials and finished goods
to the market place, Celsis' products facilitate increased manufacturing
productivity and improved supply chain management.

Celsis International plc is listed on the London Stock Exchange (CEL.L).
Further information can be found on the Company's website at www.celsis.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
TSTFGGZLNNVGDZM